This study demonstrated the benefits of pharmacist integration into an interdisciplinary to treatment patients with chronic HCV. Pharmacist integration resulted in improved patient engagement, reduced provider burden, and increased rate of HCV treatment.

Prior to the release of sofosbuvir/velpatasvir/voxilaprevir, few options for retreating patients failing HCV direct acting antiviral (DAA) therapy. This study evaluated the effectiveness of sofosbuvir + simeprevir + ribavirin for 24 weeks in retreating patients who previously failed HCV treatment containing an NS5A inhibitor.

This study describes a real world cohort of HIV/HCV co-infected patients in an outpatient infectious diseases clinic with a focus on the frequency and impact of HIV antiretroviral adjustments required prior to HCV direct acting antiviral initiation.

Based on recent clinical trial data, most patients who fail HCV treatment with direct acting antiviral agents now have excellent retreatment options. In this article, we review the current state of the evidence for HCV retreatment after DAA failure.

The objective of this study was to identify factors associated with movement through the HCV CoC after referral to a multidisciplinary ID clinic to sustained virologic response (SVR), including both general and historically difficult to treat populations.

Universal HCV screening was recently suggested to have the biggest impact on cascade of care improvement. The objective of this study was to compare cascade of care completion rates among patients referred for HCV treatment from traditional referral sources to those referred from the emergency department. We found that patient demographics vary between the two referral sources and patients referred from the emergency department had significantly lower linkage and engagement in HCV care.

Given the shortage of suitable donor hearts for cardiac transplantation, and the favorable safety and efficacy of current agents used to treat hepatitis C virus(HCV), our institution recently piloted transplantation of select patients using HCV-positive donors. In the era of highly effective DAAs, the use of HCV-positive donors represents a potential approach to safely expand the donor pool.

An increasing number of specialists and non-specialists are developing clinical programs to treat and cure hepatitis C virus (HCV). The goal of this paper is to evaluate and describe optimal strategies to improve outcomes related to HCV care delivery.

This study examins the use and pharmacotherapy of direct acting antivirals to treat hepatitis C in transplant patients receiving positive donor hearts. While results of this practice have proven successful, management of drug-drug interactions between transplant medications and DAAs is necessary to ensure safety and efficacy.

This multi-site study evaluated the effectiveness of a clinical pharmacist-driven HCV delivery model in an open system. With an overall sustained virologic response (SVR) rate of 95% (per protocol), the clinical pharmacist-driven HCV treatment model was found to be effective and comparable to other real-world studies with specialist, non-specialist, and non-hepatology providers.